LDS/Medical Tests/Calcium Channel Voltage-dependent L Type alpha 1S Subunit (CACNA1S) Gene Mutation Analysis

Calcium Channel Voltage-dependent L Type alpha 1S Subunit (CACNA1S) Gene Mutation Analysis

The CACNA1S gene is located at 1q32.1 and codes for one of the five subunits, alpha 1 of the slowly inactivating L-type voltage-dependent calcium channel in skeletal muscle cells. Upon the arrival of action potential on the neuromuscular junction, these receptors trigger the release of calcium ions from the sarcoplasmic reticulum by interacting with the ryanodine receptor (coded by the RYR gene). The released calcium initiates muscular contraction. The process is also referred to as excitation-coupling.

Variants in the CASNA1S may cause formation of a defective alpha S subunit fails to open properly on the arrival of the excitatory signal, this affects the release of calcium ions, impairs muscle contraction and results in profound muscle weakness or paralysis (hypokalemic periodic paralysis). Variants are also associated with susceptibility to thyrotoxic periodic paralysis and malignant hyperthermia (MHS).

The European Malignant Hyperthermia Group (EMHG) has listed two variants that are associated with malignant hyperthermia susceptibility (MHS) in patients receiving volatile anesthetics like halothane, isoflurane, and enflurane or depolarizing muscle relaxants like succinylcholine. These patients have shown hypersensitive responses to these drugs that cause uncontrolled and dysregulated flow of calcium ions into the myoplasm. The resulting effect is muscle rigidity, hyperthermia, tachycardia, rhabdomyolysis, and acidosis which can be life-threatening. The FDA has contraindicated the use of these drugs in patients who test positive for variants. More commonly, MHS is caused by the variants in the RYR1 gene. Pharmacogenetic screening of these genes in patients with a personal or family history of adverse reactions to anesthesia is beneficial in avoiding these complications.

  • As an aid in screening for malignant hyperthermia susceptibility (MHS)
  • Important in the selection anesthesiologic agents in patients with MHS
  • May be useful in determining the cause of periodic paralysis
A positive result indicates the presence of mutation or pathogenic variants in the CACNA1S gene and thus susceptible to malignant hyperthermia and are at an increased risk of an MH reaction when administered a potent volatile anesthetic and/or succinylcholine. [The FDA has contraindicated the use of volatile anesthesia in patients who test positive. Instead, a non-triggering anesthetic such as nerve block, epidural, spinal, or total intravenous general anesthetic can be administered.] A negative result indicates the absence of mutation or pathogenic variants in the CACNA1S gene. However, RYR1 should also be evaluated as it is a more common cause of MHS.

No Pathogenic Variant Detected (susceptibility to malignant hyperthermia not rule out)

Real-time Polymerase Chain Reaction (PCR), Next-generation Sequencing (NGS), Multiplex Ligation-Dependent Probe Amplification (MLPA).

Whole blood, Lavender-top (EDTA) tube, buccal swab, saliva.

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days (preferred)
  • Frozen: 30 days
RYR1 variant analysis, STAC3 variant analysis, serum calcium, serum vitamin D, total CK, ALP, LDH, plasma myoglobin, urine myoglobin.
3-5 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login